Flow Cytometry Analysis of Pparα Receptors in Metabolic Syndrome / Studiul Receptorilor Pparα prin Metoda Citometriei în Flux în Sindromul Metabolic
References
- 1. Eckel R, Alberti KGMM, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2010;375(9710):181-3. DOI: 10.1016/S0140-6736(09)61794-3
- 2. Kahn R. Metabolic syndrome- what is the clinical usefulness? The Lancet. 2008;371(9628):1892-3. DOI: 10.1016/S0140-6736(08)60731-X
- 3. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006; 83(6):1237-7.
- 4. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK et al. Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death : a systematic review and meta-analysis of longitudinal studies, J Am Coll Cardiol. 2007;49(5):403-4. DOI: 10.1016/j. jacc.2006.09.032
- 5. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. International Diabetes Federation, Belgium, Brussels, 2013:1-155.
- 6. World Health Organization. Global Status Report on Noncommunicable Diseases 2010. World Health Organization Geneva, Switzerland, 2011:1-176.
- 7. Azhar S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiology.2010;6(5):657-91. DOI: 10.2217/fca.10.86
- 8. Cercosimo E, Defronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22(6):423-36. DOI: 10.1002/dmrr.634
- 9. Fruchart JCh. Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes and Cardiovascular Disease. Journal of American College Cardiology. 2006;48(9):24-32. DOI: 10.1016/j. jacc.2006.04.097
- 10. Kersten S, Desvergne B, Wahli W. Roles of PPARS in health and disease. Nature. 2000;405(6785):421-4. DOI: 10.1038/35013000
- 11. Ricote M, Valledor AF, Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology. 2004;24(2):230-9. DOI: 10.1161/01.ATV.0000103951.67680.B1
- 12. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28(12):551-8. DOI: 10.1016/j.it.2007.09.003
- 13. Kersten S. Regulation of nutrient metabolism and inflammation. Meyerhof W, Beisiegel U, Joost H-G(Eds), Sensory and Metabolic Control of Energy Balance, Results and Problems in Cell Differentiation 52, Springer- Verlag Berlin Heidelberg, 2010: DOI:10.1007/978-3-642-14426-4_2. DOI: 10.1007/978-3-642-14426-4_2
- 14. Silverstein R. Inflammation, atherosclerosis, and arterial thrombosis: Role of the scavenger receptor CD36. Cleveland Clinic Journal of Medicine. 2009;76(Suppl 2):S27-S30. DOI: 10.3949/ccjm.76.s2.06
- 15. Collot -Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL. CD36 and macrophages in atherosclerosis. Cardiovasc Resp. 2007;75(3):468-77. DOI: 10.1016/j.cardiores.2007.03.010
- 16. Herzenberg LA, Parks D, Sahaf B, Roederer M, Herzenberg LA. The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem. 2002;48(10):1819-27.
- 17. Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H et al. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV (H) mutation analysis. Cytometry B Clin Cytom. 2006;70(4):270-5. DOI: 10.1002/cyto.b.20134
- 18. Butts CL, Shukair SA, Duncan KM, Harris CW, Belyavskaia E, Sternberg EM . Evaluation of steroid hormone receptor protein expression in intact cells using flow cytometry. Nucl Recept Signal. 2007; DOI:10.1621/nrs.05007. DOI: 10.1621/nrs.05007
- 19. Christensen R. Testing Fisher, Neyman, Pearson and Bayes. American Statistician. 2005; 59(2):121-6. DOI: 10.1198/000313005X20871
- 20. Kreiner S, Christensen KB. Analysis of Local Dependence and Multi-dimensionality in Graphical Loglinear Rasch Models. Communications in Statistics - Theory and Methods. 2004;33(6):1239-76. DOI: 10.1081/STA-120030148
- 21. Der G, Everitt B. Statistical Analysis of Medical Data Using SAS. Boca Raton, Fl. Chapman Hall/CRC Press, 2005:1-440.
- 22. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis Atherosclerosis. 2011;217(2):492-8.
- 23. Zandbergen F, Plutzky J. PPARα in atherosclerosis and inflammation. Biochim Biophys Acta. 2007;1771(8):972-82. DOI: 10.1016/j. bbalip.2007.04.021
- 24. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005; 352(16):1685-95. DOI: 10.1056/NEJMra043430
- 25. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzales RR, Jouihan HA, Bando JK et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332(6026):243-47. DOI: 10.1126/science.1201475
- 26. Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2014;1842(3):446-62. DOI: 10.1016/j.bbadis.2013.05.017
- 27. Jacobsen E, Helmers R, Lee J, Lee N. The expanding role(s) of eosinophils in health and disease. Blood. 2012;120(19):3882-90. DOI: 10.1182/ blood-2012-06-330845
- 28. Woerly G, Honda K, Loyens M,. Papin J P, Auwerx J, Staels B et al. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med. 2003;198(3):411-21. DOI: 10.1084/jem.20021384
- 29. D’Amore S, Vacca M, Graziano G, D’Orazio A, Cariello M, Martelli N et al. Nuclear receptors expression chart in peripheral blood mononuclear cells identifies patients with Metabolic Syndrome. Biochim Biophys Acta. 2013;1832(12):2289-301. DOI: 10.1016/j.bbadis.2013.09.006
- 30. Faiola B, Peterson RA, Bordelon R, Brodie TA, Cummings CA, Romach EH et al. PPAR alpha, more than PPAR delta, Mediates the Hepatic and Skeletal Muscle Alterations Induced by the PPAR Agonist GW0742.Toxicol. Sci. 2008;105(2):384-94. DOI: 10.1093/toxsci/ kfn130
- 31. Kim CS, Park HS, Kawada T, Kim J-H, Lim D, Hubbard NE et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity related parameters. International Journal of Obesity. 2006;30(9):1347-55. DOI: 10.1038/ sj.ijo.0803259
- 32. Pasceri V, Chang J, Willerson J, Yeh ETH. Modulation of C-Reactive Protein-Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti Atherosclerosis Drugs. Circulation. 2001;103(21):2531-4. DOI: 10.1161/01.CIR.103.21.2531
- 33. Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol. 2006;44(6):440-9. DOI: 10.1016/j.vph.2006.02.006
- 34. Christiansen T, Richelsen B and Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adi pocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. International Journal of Obesity. 2005;29(1):146-50. DOI: 10.1038/ sj.ijo.0802839
- 35. Fu J, Gaetani S, Oveisi F, Verme JL, Serrano A. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature. 2003;425(6953):90-3. DOI: 10.1038/nature01921
- 36. Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia.Lipid Res. 2000;41(6):945-52.
- 37. Perreault M, Zulyniak MA, Badoud F, Stephenson S, Badawi A, Buchholz A et al. A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. PLoSOne. 2014; 9(2):e88539. DOI: 10.1371/journal.pone.0088539. DOI: 10.1371/journal.pone.0088539
- 38. Tsimihodimos V, Miltiadous G , Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: Metabolic and Pleiotropic Effects. Current Vascular Pharmacology, 2005; (1):87-98 DOI: 10.2174/1570161052773942
- 39. Wilson J, Duan R, El-Marakby A, Alhashim A and Lee DL. Peroxisome Proliferator Activated Receptor-α Agonist Slows the Progression of Hypertension, Attenuates Plasma Interleukin-6 Levels and Renal Inflammatory Markers in Angiotensin II Infused Mice. PPAR Research.2012; DOI:10.1155/2012/645969. DOI: 10.1155/2012/645969
- 40. Han J. Hajjar DP, Febbraio M, Nicholson AC. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J. Biol. Chem.1997;272(34):21654-9. DOI: 10.1074/jbc.272.34.21654
- 41. Gautam S, Banerjee M. The macrophage Ox- LDL receptor, CD36 and its association with type II diabetes mellitus. Molecular genetics and metabolism. 2011;10 (4):389-98. DOI: 10.1016/j. ymgme.2010.12.012
DOI: https://doi.org/10.2478/rrlm-2014-0036 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624 (formerly 2284-5623)
Language: English, Romanian
Page range: 427 - 438
Submitted on: Jun 15, 2014
Accepted on: Oct 3, 2014
Published on: Dec 30, 2014
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2014 Elena Popa, Florin Zugun-Eloae, Mihaela Zlei, Daniela Jitaru, Oana Maria Pintilie, Adorata Elena Coman, Maria Traian, Didona Anca Ungureanu, Eugen Carasevici, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.